200 related articles for article (PubMed ID: 22375026)
1. Reforming antiretroviral price negotiations and public procurement: the Mexican experience.
Adesina A; Wirtz VJ; Dratler S
Health Policy Plan; 2013 Jan; 28(1):1-10. PubMed ID: 22375026
[TBL] [Abstract][Full Text] [Related]
2. Negotiating antiretroviral drug prices: the experience of the Andean countries.
Seoane-Vazquez E; Rodriguez-Monguio R
Health Policy Plan; 2007 Mar; 22(2):63-72. PubMed ID: 17299024
[TBL] [Abstract][Full Text] [Related]
3. Allocating scarce financial resources for HIV treatment: benchmarking prices of antiretroviral medicines in Latin America.
Wirtz VJ; Santa-Ana-Tellez Y; Trout CH; Kaplan WA
Health Policy Plan; 2012 Dec; 27(8):638-48. PubMed ID: 22367770
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral purchasing and prescription practices in Mexico: constraints, challenges and opportunities.
Chaumont C; Bautista-Arredondo S; Calva JJ; Bahena-González RI; Sánchez-Juárez GH; González de Araujo-Muriel A; Magis-Rodríguez C; Hernández-Ávila M
Salud Publica Mex; 2015; 57 Suppl 2():s171-82. PubMed ID: 26545133
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Price Negotiations on Public Procurement Prices and Access to 8 Innovative Cancer Medicines in a Middle-Income Country: The Case of Mexico.
Moye-Holz D; van Dijk JP; Reijneveld SA; Hogerzeil HV
Value Health Reg Issues; 2019 Dec; 20():129-135. PubMed ID: 31374426
[TBL] [Abstract][Full Text] [Related]
6. Factors influencing global antiretroviral procurement prices.
Wirtz VJ; Forsythe S; Valencia-Mendoza A; Bautista-Arredondo S
BMC Public Health; 2009 Nov; 9 Suppl 1(Suppl 1):S6. PubMed ID: 19922690
[TBL] [Abstract][Full Text] [Related]
7. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
Pinheiro Edos S; Antunes OA; Fortunak JM
Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
[TBL] [Abstract][Full Text] [Related]
8. Affordability of adult HIV/AIDS treatment in developing countries: modelling price determinants for a better insight of the market functioning.
Sagaon-Teyssier L; Singh S; Dongmo-Nguimfack B; Moatti JP
J Int AIDS Soc; 2016; 19(1):20619. PubMed ID: 27765142
[TBL] [Abstract][Full Text] [Related]
9. Antiretroviral drug expenditure, pricing and judicial demand: an analysis of federal procurement data in Brazil from 2004-2011.
Luo J; Oliveira MA; Ramos MB; Maia A; Osorio-de-Castro CG
BMC Public Health; 2014 Apr; 14():367. PubMed ID: 24735589
[TBL] [Abstract][Full Text] [Related]
10. A new entity for the negotiation of public procurement prices for patented medicines in Mexico.
Gómez-Dantés O; Wirtz VJ; Reich MR; Terrazas P; Ortiz M
Bull World Health Organ; 2012 Oct; 90(10):788-92. PubMed ID: 23109747
[TBL] [Abstract][Full Text] [Related]
11. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.
Nunn AS; Fonseca EM; Bastos FI; Gruskin S; Salomon JA
PLoS Med; 2007 Nov; 4(11):e305. PubMed ID: 18001145
[TBL] [Abstract][Full Text] [Related]
12. Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases.
Waning B; Kaplan W; King AC; Lawrence DA; Leufkens HG; Fox MP
Bull World Health Organ; 2009 Jul; 87(7):520-8. PubMed ID: 19649366
[TBL] [Abstract][Full Text] [Related]
13. Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs.
Holmes CB; Coggin W; Jamieson D; Mihm H; Granich R; Savio P; Hope M; Ryan C; Moloney-Kitts M; Goosby EP; Dybul M
JAMA; 2010 Jul; 304(3):313-20. PubMed ID: 20639565
[TBL] [Abstract][Full Text] [Related]
14. An analysis of volumes, prices and pricing trends of the pediatric antiretroviral market in developing countries from 2004 to 2012.
Lee JSF; Sagaon Teyssier L; Dongmo Nguimfack B; Collins IJ; Lallemant M; Perriens J; Moatti JP
BMC Pediatr; 2016 Mar; 16():41. PubMed ID: 26979974
[TBL] [Abstract][Full Text] [Related]
15. Trends and economic stress: a challenge to universal access to antiretroviral treatment in India.
Dhamija P; Bansal D; Medhi B
Curr HIV Res; 2009 Jul; 7(4):410-7. PubMed ID: 19601776
[TBL] [Abstract][Full Text] [Related]
16. Modeling HIV/AIDS drug price determinants in Brazil: is generic competition a myth?
Meiners C; Sagaon-Teyssier L; Hasenclever L; Moatti JP
PLoS One; 2011; 6(8):e23478. PubMed ID: 21858138
[TBL] [Abstract][Full Text] [Related]
17. A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries.
Waning B; Diedrichsen E; Moon S
J Int AIDS Soc; 2010 Sep; 13():35. PubMed ID: 20840741
[TBL] [Abstract][Full Text] [Related]
18. Antiretroviral procurement and supply chain management.
Ripin DJ; Jamieson D; Meyers A; Warty U; Dain M; Khamsi C
Antivir Ther; 2014; 19 Suppl 3():79-89. PubMed ID: 25310145
[TBL] [Abstract][Full Text] [Related]
19. One-year assessment of joint procurement of pharmaceuticals in the public health sector in Jordan.
Al-Abbadi I; Qawwas A; Jaafreh M; Abosamen T; Saket M
Clin Ther; 2009 Jun; 31(6):1335-44. PubMed ID: 19695398
[TBL] [Abstract][Full Text] [Related]
20. Examining the production costs of antiretroviral drugs.
Pinheiro E; Vasan A; Kim JY; Lee E; Guimier JM; Perriens J
AIDS; 2006 Aug; 20(13):1745-52. PubMed ID: 16931939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]